
Drug firm Zydus Cadila on Friday said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
from IndiaTV: Google News Feed https://ift.tt/3oket9y
Leave a Comment